Business Wire

NY-ECOVADIS

13.7.2022 09:02:11 CEST | Business Wire | Press release

Share
EcoVadis Accelerates Sustainability Intelligence Capabilities with Acquisition of ecotrek

EcoVadis , the leading provider of globally trusted business sustainability ratings, today announced the acquisition of ecotrek , a sustainability data mining company. The company’s automated sustainability data collection, scanning, and analysis capabilities will complement EcoVadis’ portfolio of solutions by enhancing technical capabilities, improving customer experience, and expanding visibility with robust information about trading partners, thus accelerating the pace of its global scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005172/en/

With over 5 million company profiles already in its database, ecotrek’s sustainability data mining (SDM) capabilities make it possible to automate the gathering and integration of sustainability data into business processes. This gives EcoVadis unmatched access to company-specific insights to understand environmental, social and ethical risk and opportunity, providing even faster and more robust risk visibility for organizations across the entire supply chain.

“The acquisition of ecotrek strengthens our position as the optimal choice for companies to drive sustainability impact at scale across their value chains. We welcome ecotrek’s entrepreneurial team, technology and expertise into our purpose and culture,” said Pierre-François Thaler, co-CEO at EcoVadis. “This is an important step forward as we ramp up our investment in technology and sustainability intelligence capabilities that we are excited to bring to our global customer base.”

ecotrek’s SDM expands upon EcoVadis’ technical capabilities with automated data collection, scanning, analysis, and classification of a company’s sustainability information. This enables EcoVadis to provide even smarter and faster predictive intelligence to optimize sustainability risk management strategies. It also enables EcoVadis to enhance the quality and experience in its ratings while boosting process efficiency for improving the engagement journey with value chain partners. The combined product suite will provide an end-to-end offering from risk classification and monitoring to supplier sustainability performance improvement.

“We shaped and validated our technology around a deep and growing market need for easing and accelerating sustainability insights. EcoVadis is the ideal partner to advance our mission to help companies deploy sustainable procurement at a global scale,” said Rena Kleine, Co-CEO at ecotrek. "By joining forces with EcoVadis, our customers will realize huge benefits in product growth, ability to scale and enable them to integrate sustainability into their procurement processes quickly for maximum impact.”

In light of rising regulations, such as the German Supply Chain Act and the imminent European Directive on supply chain due diligence, the combined end-to-end offerings give customers a giant head start over their peers on monitoring and improving their supply chain to be not only compliant with this law, but to thrive in the new responsible business environment.

ecotrek’s four co-founders brought together their backgrounds in software, engineering, and applied science to create the company in 2020. They and their entire team will join the EcoVadis business and merge with the EcoVadis team in Germany. For more details, contact EcoVadis .

About EcoVadis
EcoVadis is a purpose-led company whose mission is to provide globally trusted business sustainability ratings. Businesses of all sizes rely on EcoVadis’ expert intelligence and evidence-based ratings to monitor and improve the sustainability performance of their business and trading partners. Its actionable scorecards, benchmarks, carbon action tools, and insights guide an improvement journey for environmental, social and ethical practices across 200 industry categories and 175 countries. Industry leaders such as Amazon, Johnson & Johnson, L’Oréal, Unilever, LVMH, Salesforce, Bridgestone, BASF and JPMorgan are among the 95,000 businesses that collaborate with EcoVadis to drive resilience, sustainable growth and positive impact worldwide. Learn more on ecovadis.com , Twitter or LinkedIn .

About ecotrek
ecotrek is a sustainability data mining startup focusing on automated supplier monitoring for the entire supply chain based on publicly available data points. Through machine learning enabled data collection & classification, the ecotrek SDM technology assures instant data insights for thousands of suppliers in a few hours, leading to actionable insights and improvement of the overall supply chain sustainability. Learn more on ecotrek.tech or LinkedIn .

Link:

ClickThru

Social Media:

https://www.facebook.com/ecovadis/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye